Post-Discharge Anti-Seizure Medication Use Improves Post-Stroke Survival: An Emulated Target Trial in Older Adults
Authors:
- Madhav SankaranarayananMSMadhav Sankaranarayanan
- Maria Andrea DonahueMDMaria Andrea Donahue
- Julianne D. BrooksJBJulianne D. Brooks
- Shuo SunSSShuo Sun
- Joseph P. NewhouseJNJoseph P. Newhouse
- Deborah BlackerDBDeborah Blacker
- Sebastien HaneuseSHSebastien Haneuse
- Sonia Hernández DíazSDSonia Hernández Díaz
- Lidia M.V.R. MouraLMLidia M.V.R. Moura
Preprint
Abstract
Objective: Levetiracetam is commonly prescribed for seizure prophylaxis after acute ischemic stroke (AIS) and often continued beyond discharge. While its short-term effectiveness for preventing post-stroke seizures is established, it is unclear whether prolonged use improves survival, particularly in older adults. We estimated the effect of continued levetiracetam use on 90-day mortality among Medicare beneficiaries after AIS. Methods: Using Traditional Medicare claims data (2008-2021), we identified beneficiaries aged ≥66 years hospitalized for AIS who initiated outpatient levetiracetam within 90 days of discharge. After one month of continued post-stroke use of levetiracetam (start of follow-up), we compared 90-day mortality between patients with a new levetiracetam dispensation within a 14-day grace period post-follow up and those without one. We performed cloning, censoring and weighting to address immortal time bias and estimated standardized mortality risks, risk differences, and 95% confidence intervals (CI). Results: Among 3,212 eligible beneficiaries, 1,779 (55.4%) received a new levetiracetam dispensation within the 14-day grace period. Median age was 76 years (IQR 70-83); 57.8% were female. After adjustment for demographics, hospitalization characteristics, timing of initiation, and comorbidities, continued use was associated with lower 90–day mortality than discontinuation (53 vs 62 deaths per 1,000; risk difference −9 per 1,000; 95% CI: (−12,−5)). The reduction was observed primarily among patients aged ≥75 years. Significance: Among older Medicare beneficiaries who initiated levetiracetam after AIS, continued outpatient use was associated with modestly lower 90–day mortality, particularly in those aged ≥75 years. These findings suggest potential benefits of levetiracetam continuation beyond the immediate post-stroke period.Keywords
This publication has 40 references indexed in Scilit:
- Transparent Reporting of Observational Studies Emulating a Target Trial—The TARGET StatementJAMA, 2025
- Prolonged Hospital Length of Stay Does Not Improve Functional Outcome in Acute Ischemic StrokeNeurology and Therapy, 2025
- Association of Mortality and Risk of Epilepsy With Type of Acute Symptomatic Seizure After Ischemic Stroke and an Updated Prognostic ModelJAMA Neurology, 2023
- Target Trial EmulationJAMA, 2022
- Anti-seizure medication treatment and outcomes in acute ischemic stroke patients undergoing continuous EEG monitoringNeurological Sciences, 2022
- The Effect of Antiseizure Medication Administration on Mortality and Early Posttraumatic Seizures in Critically Ill Older Adults with Traumatic Brain InjuryNeurocritical Care, 2022
- Long‐term continuation of anti‐seizure medications after acute strokeAnnals of Clinical and Translational Neurology, 2021
- Levetiracetam for Seizure Prophylaxis in Neurocritical Care: A Systematic Review and Meta-analysisNeurocritical Care, 2021
- Patterns of anticonvulsant use and adverse drug events in older adultsPharmacoepidemiology and Drug Safety, 2020
- Immortal time bias in observational studies of drug effectsPharmacoepidemiology and Drug Safety, 2007